EUVIMEDEUVIMED entdecken
Übersichtsarbeit

2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management

Haris Ali iD, Andrea Bacigalupo

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27274 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Haris Ali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Divison of Leukemia, Department of Hematology and Hemopoietic Cell Transplantation, City of Hope, Duarte, California, USA. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the only curative treatment for patients with myelofibrosis (MF). Transplant related mortality (TRM) and relapse, remain two significant complications which need to be addressed.

Aims

The aim of this manuscript is to review current available reports on changes which have recently occurred, to improve the outcome of MF patients undergoing an allogeneic HSCT.

Methods

Published papers were used to analyze different aspects of allogeneic HSCT.

Results

Changes and updates are provided on selection of patients, prognostic systems, managing splenomegaly, conditioning regimens, predicting transplant outcome, stem cell sources, stem cell donors, graft versus host disease (GvHD) prophylaxis, patients with blast phase, hematopoietic reconstitution, disease markers, donor chimerism, and treatment of relapse.

Conclusions

The review outlines new transplant platforms which are now available for patients with myelofibrosis, together with persisting problems, among which, older age combined with marrow fibrosis and an inflammatory disease. Relapse also requires aggressive monitoring of drivers mutations, and early cellular therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansTransplantation, HomologousTreatment OutcomeNeoplasm Recurrence, LocalChronic DiseaseRecurrenceRisk AssessmentTransplantation Conditioning

Autor:innen und Institutionen

  • Divison of Leukemia, Department of Hematology and Hemopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
  • Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy.

ORCID-Profile: Haris Ali

Zitieren

APA

Ali, H., & Bacigalupo, A. (2024). 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. American Journal of Hematology. https://doi.org/10.1002/ajh.27274

Vancouver

Ali H, Bacigalupo A. 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. American Journal of Hematology. 2024. doi:10.1002/ajh.27274

BibTeX
@article{Ali2024,
  author = {Ali, Haris and Bacigalupo, Andrea},
  title = {2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27274}
}
Kostenlos starten →